T1	p 70 114	postoperative rectal cancer patients treated
T2	p 259 279	polymorphism ( SNP )
T3	p 331 380	postoperative rectal cancer patients who received
T4	p 450 507	Four hundred patients with stage II and III rectal cancer
T5	p 559 566	without
T6	p 642 650	patients
T7	p 691 733	Two hundred and twenty-eight patients were
T8	p 806 823	172 patients were
T9	p 1370 1385	of 136 patients
T10	p 1576 1584	patients
T11	p 1676 1686	patients .
T12	p 1860 1883	patients without severe
T13	p 1994 2019	patients with AA genotype
T14	p 2165 2181	patients with AA
T15	p 2390 2394	risk
T16	p 2541 2588	stage II and III rectal cancer patients treated
T17	i 24 42	A870G polymorphism
T18	i 120 159	adjuvant concurrent chemoradiotherapy ]
T19	i 248 279	nucleotide polymorphism ( SNP )
T20	i 381 437	capecitabine-based postoperative chemoradiotherapy ( CRT
T21	i 531 534	CRT
T22	i 538 578	capecitabine with or without oxaliplatin
T23	i 584 595	accumulated
T24	i 747 799	concurrent capecitabine and radiotherapy ( Cap-CRT )
T25	i 837 897	capecitabine and oxaliplatin plus radiotherapy ( Cap-Oxa-CRT
T26	i 946 952	Common
T27	i 1004 1014	CTCAE v3.0
T28	i 1090 1151	chain reaction-based restriction fragment length polymorphism
T29	i 1154 1162	PCR-RFLP
T30	i 1259 1260	)
T31	i 1312 1320	computed
T32	i 1326 1334	logistic
T33	i 1449 1466	genotypes GG , GA
T34	i 1716 1733	genotypes GG , GA
T35	i 2085 2103	GG or GA genotypes
T36	i 2145 2156	Cap-Oxa-CRT
T37	i 2306 2314	GG or GA
T38	i 2338 2345	Cap-CRT
T39	i 2358 2361	SNP
T40	i 2456 2461	CCND1
T41	i 2594 2665	adjuvant concurrent chemoradiotherapy of capecitabine and oxaliplatin .
T42	o 46 66	acute adverse events
T43	o 299 327	acute adverse events ( AEs )
T44	o 798 799	)
T45	o 898 899	)
T46	o 902 916	Adverse events
T47	o 953 985	Terminology Criteria for Adverse
T48	o 1111 1153	restriction fragment length polymorphism (
T49	o 1219 1222	AEs
T50	o 1246 1260	ratios ( ORs )
T51	o 1293 1296	CIs
T52	o 1467 1473	and AA
T53	o 1604 1614	. Diarrhea
T54	o 1640 1659	and severe diarrhea
T55	o 1734 1740	and AA
T56	o 1884 1894	diarrhea .
T57	o 1946 1955	1.66-fold
T58	o 1975 1990	severe diarrhea
T59	o 2200 2209	2.34-fold
T60	o 2229 2244	severe diarrhea
T61	o 2312 2324	GA genotypes
T62	o 2398 2415	severe diarrhea .
T63	o 2514 2523	acute AEs